Trial pipeline · NCT05796752
Behavioral Treatment and Memantine in Body Focused Repetitive Behaviors
Phase 2/3 Active, not recruiting status last verified 2026-07
A registered clinical trial, reproduced from its ClinicalTrials.gov record. Every value on this page is a field on that record. Nothing on this page is a finding, an assessment or a recommendation.
The registered record
- Accession number
- NCT05796752
- Lead sponsor
- University of Chicago (other)
- Registered condition naming hair loss
- Trichotillomania (Hair-Pulling Disorder)
- Also registered on this record
- Skin-Picking
- Official title
- Single-Group Crossover Trial Comparing Behavioral Treatment to Memantine in Body Focused Repetitive Behaviors
The first row holds the registered condition that placed this trial on the pipeline; the second holds everything else the sponsor registered on the same record. Both are shown, and shown apart rather than shaded differently, because leaving the second out would make this trial look more like a hair-loss study than its registration says it is — and because a distinction carried only by colour is not a distinction for every reader.
Interventions
- DrugMemantine
- BehavioralComB Behavioral Therapy
Names and types as registered. The sponsors' free-text descriptions of these interventions are not reproduced: they are written by the party with an interest in the result, and reprinting them inside this site's layout would lend them this site's voice.
Design
- Study type
- interventional
- Phase
- Phase 2/3
- Allocation
- na
- Masking
- none
- Primary purpose
- treatment
- Enrolment
- 26 participants (actual)
- Sites
- 1 location in United States
What it measures
National Institutes of Mental Health Symptom Severity Scale (for trichotillomania or Skin Picking) (NIMH-TSS or NIMH-SPS)
Time frame: The primary efficacy endpoints will be the change in these measures from baseline to week 8 in memantine treatment vs. ComB treatment.
Primary outcome measures only, as registered. What a trial chose to measure, and when, is the most informative thing about it that is knowable before it reports — a hair-count endpoint at 24 weeks and a patient-satisfaction endpoint at 12 weeks are not the same study.
Who can take part
- Sex
- all
- Age
- 18 Years
- Healthy volunteers
- not accepted
A summary of three registered fields, not the eligibility criteria. The full inclusion and exclusion criteria, the recruiting sites and the study contacts are on the registry record, which is the only place they are maintained. This site has no relationship with this trial and cannot refer anyone to it.
Registered dates
- Study start
- 2 August 2023 (actual)
- Primary completion
- 16 April 2026 (actual)
- Study completion
- June 2027 (estimated)
- First posted
- 3 April 2023 (actual)
- Last update posted
- 7 July 2026 (actual)
"Estimated" and "actual" are the registry's own labels: an estimated date is a plan, and plans move. A date is printed at the precision it was registered at: this record registers a primary completion to the day, so a day is what is shown. Where a sponsor registers only a month, only a month is shown.
Results
This trial has not reported results. ClinicalTrials.gov holds no results record for it. That is the ordinary state of a trial that is running or about to run, and it means there is nothing here to tell you about whether the intervention works — including nothing negative. If this page implied otherwise it would be wrong.
On this site
Guides covering the condition this trial is registered for. They are about published evidence; this page is about a registration, and the two do not overlap.
Where this came from
Read from the ClinicalTrials.gov API on 6 September 2026 and rebuilt into this page without alteration. ClinicalTrials.gov is a service of the U.S. National Library of Medicine and is the authority on this record; where this page and the registry disagree, the registry is right. This page is not affiliated with or endorsed by NLM or NIH, or with the sponsor of this trial.
Open NCT05796752 on ClinicalTrials.gov · All 157 trials in the pipeline